Truist Financial Cuts Intuitive Surgical (NASDAQ:ISRG) Price Target to $605.00

Intuitive Surgical (NASDAQ:ISRG) had its price objective reduced by Truist Financial from $666.00 to $605.00 in a research report sent to investors on Monday morning, Marketbeat Ratings reports. They currently have a buy rating on the medical equipment provider’s stock.

ISRG has been the topic of a number of other research reports. Bernstein Bank boosted their price objective on shares of Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a report on Monday, January 27th. BTIG Research boosted their price objective on shares of Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Raymond James boosted their price objective on shares of Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a report on Friday, January 24th. Morgan Stanley raised shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $522.00 to $650.00 in a report on Monday, December 2nd. Finally, Barclays lifted their target price on shares of Intuitive Surgical from $610.00 to $674.00 in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $611.86.

Intuitive Surgical Trading Up 1.7 %

ISRG stock opened at $492.06 on Monday. The company has a market cap of $175.26 billion, a P/E ratio of 76.76, a P/E/G ratio of 5.85 and a beta of 1.43. Intuitive Surgical has a 52 week low of $364.17 and a 52 week high of $616.00. The company’s 50-day moving average price is $564.39 and its 200 day moving average price is $531.62.

Insider Activity

In related news, EVP Robert Desantis sold 11,545 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $499.22, for a total transaction of $5,763,494.90. Following the completion of the transaction, the executive vice president now owns 5,224 shares of the company’s stock, valued at approximately $2,607,925.28. This represents a 68.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Fredrik Widman sold 810 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $573.78, for a total transaction of $464,761.80. Following the sale, the vice president now owns 473 shares of the company’s stock, valued at approximately $271,397.94. This represents a 63.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,754 shares of company stock valued at $17,691,621 over the last 90 days. Insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

Institutional investors have recently bought and sold shares of the business. Atala Financial Inc purchased a new position in shares of Intuitive Surgical in the fourth quarter valued at $25,000. Berbice Capital Management LLC acquired a new stake in shares of Intuitive Surgical in the 4th quarter worth about $26,000. Parvin Asset Management LLC acquired a new stake in shares of Intuitive Surgical in the 4th quarter worth about $26,000. BankPlus Trust Department bought a new position in Intuitive Surgical in the 4th quarter valued at about $28,000. Finally, Hurley Capital LLC bought a new position in shares of Intuitive Surgical during the 4th quarter valued at about $28,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.